Dare Bioscience Inc (NASDAQ: DARE) announced encouraging topline consequences from its Phase 1 scientific pilot of DARE-HRT1. DARE-HRT1 is a novel IVR intended to transport bio-identical 17β-estradiol and bio-identical progesterone unceasingly over 28 days. Consequences Support Latent as the First Cyclic Treatment for both the Vasomotor and the Vaginal Indications […]